We can’t show the full text here under this license. Use the link below to read it at the source.
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
Semaglutide improves heart and metabolism health risks in adults with overweight or obesity
AI simplified
Abstract
1961 participants in the STEP 1 trial and 803 in STEP 4 showed significant improvements in various cardiometabolic risk factors with semaglutide 2.4 mg.
- Semaglutide treatment resulted in greater reductions in waist circumference, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, fasting serum insulin, and lipids compared to placebo.
- Weight loss categories indicated that reductions in systolic blood pressure, non-HDL cholesterol, low-density lipoprotein cholesterol, and fasting plasma glucose were generally more pronounced with semaglutide.
- Non-significant reductions in atherosclerotic cardiovascular disease risk were observed with semaglutide when compared to placebo.
- Improvements in waist circumference, systolic blood pressure, fasting plasma glucose, fasting serum insulin, and lipids were maintained during continued semaglutide treatment but deteriorated after switching to placebo.
- There were net reductions in the use of antihypertensive and lipid-lowering medications with semaglutide compared to placebo in both trials.
AI simplified
Key numbers
51.5%
Increase in ACC/AHA BP Target Achievement
Proportion of participants achieving <130/80 mmHg at week 68
−12.4 percentage points
Weight Loss Difference
Estimated treatment difference in weight loss from baseline to week 68 in STEP 1
N/A
Reduction in Antihypertensive Medication Use
Proportion of participants decreasing or stopping antihypertensive medications